Cogent Biosciences, Inc. (COGT)
Largest Insider Buys in Sector
COGT Stock Price History Chart
COGT Stock Performance
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly …
Insider Activity of Cogent Biosciences, Inc.
Over the last 12 months, insiders at Cogent Biosciences, Inc. have bought $0 and sold $0 worth of Cogent Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Cogent Biosciences, Inc. have bought $9.75M and sold $473,103 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 800,000 shares for transaction amount of $9.6M was made by Fairmount Funds Management LLC (10 percent owner) on 2023‑06‑09.
List of Insider Buy and Sell Transactions, Cogent Biosciences, Inc.
| 2023-06-09 | 10 percent owner | 800,000 0.9139% | $12.00 | $9.6M | -33.60% | |||
| 2022-06-16 | 1.2M 0.9424% | $8.25 | $9.9M | +55.51% | ||||
| 2021-04-26 | Sale | Chief Financial Officer | 17,813 0.015% | $8.86 | $157,823 | -6.66% | ||
| 2020-05-12 | Sale | 10 percent owner | 98,200 0.0043% | $0.46 | $45,545 | +429.08% | ||
| 2020-05-11 | Sale | 10 percent owner | 100,000 0.0043% | $0.46 | $45,496 | +440.83% | ||
| 2020-05-08 | Sale | 10 percent owner | 100,000 0.0044% | $0.46 | $46,390 | +433.33% | ||
| 2020-05-07 | Sale | 10 percent owner | 100,000 0.0039% | $0.41 | $41,430 | +482.93% | ||
| 2020-05-06 | Sale | 10 percent owner | 1,800 <0.0001% | $0.40 | $722 | +524.04% | ||
| 2020-05-05 | Sale | 10 percent owner | 135,484 0.0052% | $0.40 | $54,437 | +508.44% | ||
| 2020-05-04 | Sale | 10 percent owner | 4,795 0.0002% | $0.40 | $1,921 | +508.44% | ||
| 2020-05-01 | Sale | 10 percent owner | 800 <0.0001% | $0.41 | $328 | +506.21% | ||
| 2020-04-30 | Sale | 10 percent owner | 75,994 0.0029% | $0.40 | $30,557 | +465.99% | ||
| 2020-04-29 | Sale | 10 percent owner | 382,927 0.0148% | $0.41 | $155,507 | +508.44% | ||
| 2020-04-28 | Sale | 10 percent owner | 15,048 0.0006% | $0.41 | $6,168 | +479.46% | ||
| 2020-04-27 | Sale | 10 percent owner | 242,579 0.0093% | $0.40 | $97,808 | +508.44% | ||
| 2020-04-20 | Sale | 10 percent owner | 12,606 0.0005% | $0.40 | $5,050 | +524.04% | ||
| 2020-04-17 | Sale | 10 percent owner | 65,540 0.0024% | $0.39 | $25,574 | +525.64% | ||
| 2020-04-16 | Sale | 10 percent owner | 600 <0.0001% | $0.38 | $230 | +566.78% | ||
| 2020-04-15 | Sale | 10 percent owner | 82,782 0.003% | $0.38 | $31,797 | +549.00% | ||
| 2020-04-14 | Sale | 10 percent owner | 98,973 0.0038% | $0.40 | $39,721 | +512.26% |
Insider Historical Profitability
| FROST PHILLIP MD ET AL | 15734874 14.2446% | $7.84 | 6 | 0 | ||
| Schulke Ryan | Chief Executive Officer | 6364537 5.7617% | $7.84 | 9 | 0 | +150.58% |
| Conlin Matthew | President | 4437980 4.0177% | $7.84 | 7 | 0 | +150.58% |
| Booth Bruce | director | 3361535 3.0432% | $7.84 | 1 | 0 | <0.0001% |
| Atlas Venture Fund IX, L.P. | 10 percent owner | 3361535 3.0432% | $7.84 | 1 | 0 | <0.0001% |